The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes—A Report From the Children's Oncology Group
Open accessAbstract
Purpose: Carbonyl reductases (CBRs) catalyze reduction of anthracyclines to cardiotoxic alcohol metabolites. Polymorphisms in CBR1 and CBR3 influence synthesis of these metabolites. We examined whether single nucleotide polymorphisms in CBR1 (CBR1 1096G>A) and/or CBR3 (CBR3 V244M) modified the dose-dependent risk of anthracycline-related cardiomyopathy in childhood cancer survivors. Patients and Methods: One hundred seventy survivors with cardiomyopathy (patient cases) were compared with 317 survivors with no cardiomyopathy (controls; matched on cancer diagnosis, year of diagnosis, length of follow-up, and race/ethnicity) using conditional logistic regression techniques. Results: A dose-dependent association was observed between cumulative anthracycline exposure and cardiomyopathy risk (0 mg/m 2 : reference; 1 to 100 mg/m 2 : odds ratio [OR], 1.65; 101 to 150 mg/m 2 : OR, 3.85; 151 to 200 mg/m 2 : OR, 3.69; 201 to 250 mg/m 2 : OR, 7.23; 251 to 300 mg/m 2 : OR, 23.47; > 300 mg/m 2 : OR, 27.59; P trend < .001). Among individuals carrying the variant A allele (CBR1:GA/AA and/or CBR3:GA/AA), exposure to low- to moderate-dose anthracyclines (1 to 250 mg/m 2 ) did not increase the risk of cardiomyopathy. Among individuals with CBR3 V244M homozygous G genotypes (CBR3:GG), exposure to low- to moderate-dose anthracyclines increased cardiomyopathy risk when compared with individuals with CBR3:GA/AA genotypes unexposed to anthracyclines (OR, 5.48; P = .003), as well as exposed to low- to moderate-dose anthracyclines (OR, 3.30; P = .006). High-dose anthracyclines (> 250 mg/m 2 ) were associated with increased cardiomyopathy risk, irrespective of CBR genotype status. Conclusion: This study demonstrates increased anthracycline-related cardiomyopathy risk at doses as low as 101 to 150 mg/m 2 . Homozygosis for G allele in CBR3 contributes to increased cardiomyopathy risk associated with low- to moderate-dose anthracyclines, such that there seems to be no safe dose for patients homozygous for the CBR3 V244M G allele. These results suggest a need for targeted intervention for those at increased risk of cardiomyopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
A structural approach to selection bias
Hernán, M. A., Hernández-Díaz, S., & Robins, J. M. (2004) · Epidemiology · doi:10.1097/01.ede.0000135174.63482.43 · Cited by 2,844 · cited 1×
“Presence of survival bias risks underascertainment of genotypes associated with high lethality, with consequent underestimation of disease risk effect size for those genotypes associated with both increased disease risk and disease-associated lethality.(29) Using the methodology developed by Anderson et al(30) to esti…”
MethodGrier, H. E., Krailo, M. D., Tarbell, N. J., Link, M. P., Fryer, C. J. H., Pritchard, D. J., Gebhardt, M. C., Dickman, P. S., Perlman, E. J., Meyers, P. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020890 · Cited by 1,328
Mulrooney, D. A., Yeazel, M. W., Kawashima, T., Mertens, A. C., Mitby, P., Stovall, M., Donaldson, S. S., Green, D. M., Sklar, C. A., Robison, L. L., et al. (2009) · BMJ · doi:10.1136/bmj.b4606 · Cited by 1,166
Self-citationLipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Dalton, V. M., Mone, S. M., Gelber, R. D., & Colan, S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.121 · Cited by 727
Anthracycline Cardiotoxicity: From Bench to Bedside
Gianni, L., Herman, E. H., Lipshultz, S. E., Minotti, G., Sarvazyan, N., & Sawyer, D. B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9401 · Cited by 454
Wouters, K. A., Kremer, L. C. M., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05759.x · Cited by 453
Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol.
Olson, R. D., Mushlin, P. S., Brenner, D. E., Fleischer, S., Cusack, B. J., Chang, B. K., & Boucek, R. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.10.3585 · Cited by 357
Kremer, L. C. M., van der Pal, H. J. H., Offringa, M., van Dalen, E. C., & Voûte, P. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf167 · Cited by 354
Granowetter, L., Womer, R., Devidas, M., Krailo, M., Wang, C., Bernstein, M., Marina, N., Leavey, P., Gebhardt, M., Healey, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1478 · Cited by 330
Boucek, R. J., Olson, R. D., Brenner, D. E., Ogunbunmi, E. M., Inui, M., & Fleischer, S. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47666-1 · Cited by 172
Olson, L. E., Bedja, D., Alvey, S. J., Cardounel, A. J., Gabrielson, K. L., & Reeves, R. H. (2003) · PubMed · Cited by 165
Cardiotoxicity of Antitumor Drugs
Menna, P., Salvatorelli, E., & Minotti, G. (2008) · Chemical Research in Toxicology · doi:10.1021/tx800002r · Cited by 163
New Developments in Anthracycline-Induced Cardiotoxicity
Mordente, A., Meucci, E., Silvestrini, A., Martorana, G. E., & Giardina, B. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788186228 · Cited by 112
Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues.
Stewart, D. J., Grewaal, D. S., Green, R. M., Mikhael, N. Z., Goel, R., Montpetit, V., & Redmond, M. D. (1994) · PubMed · Cited by 87
The Effect of Survival Bias on Case-Control Genetic Association Studies of Highly Lethal Diseases
Anderson, C. D., Nalls, M. A., Biffi, A., Rost, N. S., Greenberg, S. M., Singleton, A., Meschia, J. F., & Rosand, J. M. (2011) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.110.957928 · Cited by 66
Mordente, A., Minotti, G., Martorana, G. E., Silvestrini, A., Giardina, B., & Meucci, E. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00442-8 · Cited by 61
Bryant, J., Picot, J., Levitt, G., Sullivan, I. D., Baxter, L., & Clegg, A. J. (2007) · Health Technology Assessment · doi:10.3310/hta11270 · Cited by 59
Naturally Occurring Variants of Human CBR3 Alter Anthracycline In Vitro Metabolism
Bains, O. S., Karkling, M. J., Lubieniecka, J. M., Grigliatti, T. A., Reid, R. E., & Riggs, K. W. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.160614 · Cited by 50
Regulation of Human Carbonyl Reductase 3 (CBR3; SDR21C2) Expression by Nrf2 in Cultured Cancer Cells
Ebert, B., Kisiela, M., Malátková, P., El-Hawari, Y., & Maser, E. (2010) · Biochemistry · doi:10.1021/bi100814d · Cited by 48
Lakhman, S. S., Chen, X., González-Covarrubias, V., Schuetz, E. G., & Blanco, J. G. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.035550 · Cited by 39
Self-citationAnthracyclines in haematology: pharmacokinetics and clinical studies
Johnson, S. A., & Richardson, D. S. (1998) · Blood Reviews · doi:10.1016/s0268-960x(98)90030-3 · Cited by 36
Kalabus, J. L., Sanborn, C. C., Jamil, R. G., Cheng, Q., & Blanco, J. G. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035550 · Cited by 25
Self-citation
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Bozkurt, B., Colvin, M., Cook, J., Cooper, L. T., Deswal, A., Fonarow, G. C., Francis, G. S., Lenihan, D., Lewis, E. F., McNamara, D. M., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000455 · Cited by 891
Armenian, S. H., Hudson, M. M., Mulder, R. L., Chen, M. H., Constine, L. S., Dwyer, M., Nathan, P. C., Tissing, W. J. E., Shankar, S., Sieswerda, E., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70409-7 · Cited by 570
Self-citationAnthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention
Henriksen, P. A. (2018) · Heart · doi:10.1136/heartjnl-2017-312103 · Cited by 536
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 507
Metadata
- Authors
- Blanco, J. G., Sun, C.-L., Landier, W., Chen, L., Esparza-Duran, D., Leisenring, W., Mays, A., Friedman, D. L., Ginsberg, J. P., Hudson, M. M., Neglia, J. P., Oeffinger, K. C., Ritchey, A. K., Villaluna, D., Relling, M. V., & Bhatia, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-05-01
- Volume
- 30
- Issue
- 13
- Pages
- 1415-1421
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2138105710
- Cited by
- 372
- References
- 23
- FWCI
- 13.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.